- Home
- IPSC vs SLS Comparison
IPSC vs SLS Comparison
Compare IPSC & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- SLS
- Stock Information
- Founded
- IPSC 2019
- SLS 2012
- Country
- IPSC United States
- SLS United States
- Employees
- IPSC N/A
- SLS N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- SLS Health Care
- Exchange
- IPSC Nasdaq
- SLS Nasdaq
- Market Cap
- IPSC 77.3M
- SLS 70.1M
- IPO Year
- IPSC 2021
- SLS N/A
- Fundamental
- Price
- IPSC $0.89
- SLS $1.15
- Analyst Decision
- IPSC Strong Buy
- SLS
- Analyst Count
- IPSC 4
- SLS 0
- Target Price
- IPSC $11.00
- SLS N/A
- AVG Volume (30 Days)
- IPSC 562.3K
- SLS 1.3M
- Earning Date
- IPSC 03-13-2025
- SLS 11-13-2024
- Dividend Yield
- IPSC N/A
- SLS N/A
- EPS Growth
- IPSC N/A
- SLS N/A
- EPS
- IPSC N/A
- SLS N/A
- Revenue
- IPSC $2,684,000.00
- SLS N/A
- Revenue This Year
- IPSC $230.51
- SLS N/A
- Revenue Next Year
- IPSC $31.87
- SLS N/A
- P/E Ratio
- IPSC N/A
- SLS N/A
- Revenue Growth
- IPSC 7.88
- SLS N/A
- 52 Week Low
- IPSC $0.87
- SLS $0.50
- 52 Week High
- IPSC $5.51
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- IPSC 33.61
- SLS 62.46
- Support Level
- IPSC $0.87
- SLS $0.87
- Resistance Level
- IPSC $0.95
- SLS $1.01
- Average True Range (ATR)
- IPSC 0.09
- SLS 0.08
- MACD
- IPSC -0.00
- SLS 0.02
- Stochastic Oscillator
- IPSC 11.39
- SLS 85.94
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.